Group 1 - The company has issued a total of 160 million new shares at a subscription price of HKD 0.097 per share, with 30 million shares allocated to Subscriber I, 20 million shares to Subscriber II, and 110 million shares to Subscriber III [1] Group 2 - The board has discussed diversifying its business, recognizing that pharmaceuticals and healthcare are core to the "Healthy China 2030" national strategy, benefiting from trends such as an aging population and increasing chronic diseases [2] - The company has a solid foundation in drug production and has shown stable performance in recent years, although international market expansion has faced significant challenges due to varying regulatory requirements [2] - The board sees greater potential in expanding healthcare business overseas, as it typically faces less stringent regulations and faster market entry, particularly in emerging markets with growing middle classes and rising healthcare spending [2] - The new healthcare business is expected to synergize with the company's existing manufacturing infrastructure and distribution network, leveraging the experience of board members in medical devices, diagnostic services, and healthcare investment management [2] - The company plans to strategically allocate approximately 70% of the net proceeds from the share issuance to the startup costs of the new business, including product development, operational expenses, marketing, and pilot projects, while the remaining 30% will be reserved for working capital [2] - This phased strategy aims to systematically establish the healthcare business while maintaining financial flexibility [2]
精优药业(00858)完成配售合共1.6亿股